» Articles » PMID: 33155752

Alzheimer's Amyloid β Heterogeneous Species Differentially Affect Brain Endothelial Cell Viability, Blood-brain Barrier Integrity, and Angiogenesis

Overview
Journal Aging Cell
Specialties Cell Biology
Geriatrics
Date 2020 Nov 6
PMID 33155752
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Impaired clearance in the Alzheimer's Disease (AD) brain is key in the formation of Aβ parenchymal plaques and cerebrovascular deposits known as cerebral amyloid angiopathy (CAA), present in >80% of AD patients and ~50% of non-AD elderly subjects. Aβ deposits are highly heterogeneous, containing multiple fragments mostly derived from catabolism of Aβ40/Aβ42, which exhibit dissimilar aggregation properties. Remarkably, the role of these physiologically relevant Aβ species in cerebrovascular injury and their impact in vascular pathology is unknown. We sought to understand how heterogeneous Aβ species affect cerebral endothelial health and assess whether their diverse effects are associated with the peptides aggregation propensities. We analyzed cerebral microvascular endothelial cell (CMEC) viability, blood-brain barrier (BBB) permeability, and angiogenesis, all relevant aspects of brain microvascular dysfunction. We found that Aβ peptides and fragments exerted differential effects on cerebrovascular pathology. Peptides forming mostly oligomeric structures induced CMEC apoptosis, whereas fibrillar aggregates increased BBB permeability without apoptotic effects. Interestingly, all Aβ species tested inhibited angiogenesis in vitro. These data link the biological effects of the heterogeneous Aβ peptides to their primary structure and aggregation, strongly suggesting that the composition of amyloid deposits influences clinical aspects of the AD vascular pathology. As the presence of predominant oligomeric structures in proximity of the vessel walls may lead to CMEC death and induction of microhemorrhages, fibrillar amyloid is likely responsible for increased BBB permeability and associated neurovascular dysfunction. These results have the potential to unveil more specific therapeutic targets and clarify the multifactorial nature of AD.

Citing Articles

Synthetic strategies and medicinal chemistry perspectives of dual acting carbonic anhydrase modulators with monoamine oxidase and cholinesterase inhibitors.

Bindra S, Mostafa E, Abdelgawad M, Selim S, Kumar S, Mathew B RSC Med Chem. 2025; .

PMID: 39925735 PMC: 11799932. DOI: 10.1039/d4md00837e.


Lipidopathy disrupts peripheral and central amyloid clearance in Alzheimer's disease: Where are our knowledge.

Darabi S, Charkhat Gorgich E, Moradi F, Rustamzadeh A IBRO Neurosci Rep. 2025; 18:191-199.

PMID: 39906286 PMC: 11791331. DOI: 10.1016/j.ibneur.2025.01.004.


The Aβ:Aβ ratio modulates aggregation in beta-amyloid oligomers and drives metabolic changes and cellular dysfunction.

Haessler A, Gier S, Jung N, Windbergs M Front Cell Neurosci. 2024; 18:1516093.

PMID: 39717390 PMC: 11664223. DOI: 10.3389/fncel.2024.1516093.


Microglia degrade Alzheimer's amyloid-beta deposits extracellularly via digestive exophagy.

Jacquet R, Gonzalez Ibanez F, Picard K, Funes L, Khakpour M, Gouras G Cell Rep. 2024; 43(12):115052.

PMID: 39644493 PMC: 11760508. DOI: 10.1016/j.celrep.2024.115052.


Endothelial Dysfunctions in Blood-Brain Barrier Breakdown in Alzheimer's Disease: From Mechanisms to Potential Therapies.

Yue Q, Leng X, Xie N, Zhang Z, Yang D, Man Hoi M CNS Neurosci Ther. 2024; 30(11):e70079.

PMID: 39548663 PMC: 11567945. DOI: 10.1111/cns.70079.


References
1.
Davis J, Van Nostrand W . Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. Proc Natl Acad Sci U S A. 1996; 93(7):2996-3000. PMC: 39749. DOI: 10.1073/pnas.93.7.2996. View

2.
Zampar S, Klafki H, Sritharen K, Bayer T, Wiltfang J, Rostagno A . N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer's disease. Neuropathol Appl Neurobiol. 2020; 46(7):673-685. PMC: 8082844. DOI: 10.1111/nan.12637. View

3.
Montagne A, Nation D, Sagare A, Barisano G, Sweeney M, Chakhoyan A . APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020; 581(7806):71-76. PMC: 7250000. DOI: 10.1038/s41586-020-2247-3. View

4.
Selkoe D, Hardy J . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8(6):595-608. PMC: 4888851. DOI: 10.15252/emmm.201606210. View

5.
Cleary J, Walsh D, Hofmeister J, Shankar G, Kuskowski M, Selkoe D . Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2004; 8(1):79-84. DOI: 10.1038/nn1372. View